CRISPR Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances) · 96.4M shares · +9%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$81M (gross $57K, SBC $81M)
Reference price $55.62 · est. market cap ~$5.4B — last insider sale, 2026-05-29 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
B70Leading gene-editing franchise with the first approved CRISPR therapy, exceptional cash, and a broad in vivo/CAR-T/regenerative pipeline.
Strengths
- CASGEVY is the first approved CRISPR/Cas9 therapy (with Vertex) — a landmark, durable platform validation and competitive moat
- $1.98B cash (96th pct) and ~22.8 quarters runway (94th pct) fund a deep multi-franchise pipeline
- Net income growth 83rd pct and ROA 72nd pct relative to sector
Risks
- Deeply negative margins (net -166%, operating -189%, 8th pct) and revenue -91% as CASGEVY royalties ramp slowly
- Allogeneic CAR-T CTX110 was terminated (poor durability); newer assets are early and unproven
- Vertex controls the lead CASGEVY economics and program
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -16569.8%)
- Cash burnNegative free cash flow (-345.9M)
- Chronic dilutionShare count +9%/yr over 4y (dilution, book value/share -42%)
- Strong balance sheetStrong balance sheet — $2.0B cash & investments, ~23 quarters of runway
- Insider sellingInsider selling — 20 open-market sale(s) by 4 insider(s) (cluster of 4 insiders, ~$12M, last 6mo) Form 4 ↗
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-18933.6%
Net margin
-16569.8%
Return on equity
-30.3%
Return on assets
-25.7%
Revenue growth (QoQ)
68.8%
Current ratio
13.3×
Free cash flow
-$346M
EBITDA
-$645M
Tangible book value
$1.9B
Cash & investments
$2.0B
Cash runway
23q
Stock comp / revenue
2065.5%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-29 | Patel Naimish | Sell | 3.8K | $55.62 |
| 2026-05-28 | Patel Naimish | Option exercise | 10K | — |
| 2026-03-23 | Prasad Raju | Sell | 3.7K | $46.78 |
| 2026-03-23 | KASINGER JAMES R. | Sell | 3.2K | $46.78 |
| 2026-03-23 | Kulkarni Samarth | Sell | 10K | $46.78 |
| 2026-03-20 | Kulkarni Samarth | Option exercise | 20K | — |
| 2026-03-20 | KASINGER JAMES R. | Option exercise | 6.2K | — |
| 2026-03-20 | Prasad Raju | Option exercise | 6.2K | — |
| 2026-03-16 | Prasad Raju | Sell | 4.0K | $48.26 |
| 2026-03-16 | KASINGER JAMES R. | Sell | 3.5K | $48.26 |
| 2026-03-16 | Kulkarni Samarth | Sell | 10K | $48.26 |
| 2026-03-16 | Patel Naimish | Sell | 3.1K | $48.26 |
| 2026-03-16 | Prasad Raju | Sell | 5.8K | $48.26 |
| 2026-03-16 | Prasad Raju | Gift | 750 | — |
| 2026-03-14 | Prasad Raju | Option exercise | 10K | — |
| 2026-03-14 | Patel Naimish | Option exercise | 8.1K | — |
| 2026-03-14 | Prasad Raju | Option exercise | 6.9K | — |
| 2026-03-14 | KASINGER JAMES R. | Option exercise | 6.9K | — |
| 2026-03-14 | Kulkarni Samarth | Option exercise | 21K | — |
| 2026-03-11 | Kulkarni Samarth | Sell | 9.8K | $52.80 |
| 2026-03-11 | KASINGER JAMES R. | Sell | 2.8K | $52.80 |
| 2026-03-10 | Kulkarni Samarth | Option exercise | 19K | — |
| 2026-03-10 | KASINGER JAMES R. | Option exercise | 5.5K | — |
| 2026-02-19 | Kulkarni Samarth | Sell | 7.0K | $52.58 |
| 2026-02-19 | KASINGER JAMES R. | Sell | 2.1K | $52.58 |
| 2026-02-18 | Kulkarni Samarth | Option exercise | 13K | — |
| 2026-02-18 | KASINGER JAMES R. | Option exercise | 3.8K | — |
| 2026-01-22 | Kulkarni Samarth | Sell | 60K | $60.23 |
| 2026-01-22 | Prasad Raju | Option exercise | 35K | $45.15 |
| 2026-01-22 | Prasad Raju | Sell | 35K | $60.19 |
| 2026-01-20 | Kulkarni Samarth | Sell | 21K | $51.61 |
| 2026-01-20 | Kulkarni Samarth | Sell | 8.6K | $52.10 |
| 2026-01-06 | Prasad Raju | Option exercise | 23K | $45.15 |
| 2026-01-06 | Prasad Raju | Option exercise | 6.3K | $44.31 |
| 2026-01-06 | Prasad Raju | Sell | 19K | $60.18 |
| 2026-01-06 | Prasad Raju | Sell | 5.0K | $60.00 |
| 2026-01-06 | Prasad Raju | Sell | 5.8K | $60.21 |
| 2025-12-22 | Prasad Raju | Sell | 3.5K | $55.10 |
| 2025-12-22 | Prasad Raju | Sell | 5.5K | $56.33 |
| 2025-12-22 | Prasad Raju | Sell | 1.0K | $56.89 |
| 2025-12-18 | Kulkarni Samarth | Gift | 30K | — |
| 2025-10-17 | Kulkarni Samarth | Sell | 51K | $67.91 |
| 2025-10-16 | Kulkarni Samarth | Option exercise | 100K | — |
| 2025-10-14 | Kulkarni Samarth | Sell | 4.2K | $66.60 |
| 2025-10-14 | KASINGER JAMES R. | Sell | 1.1K | $66.60 |
| 2025-10-13 | Kulkarni Samarth | Option exercise | 8.3K | — |
| 2025-10-13 | KASINGER JAMES R. | Option exercise | 2.1K | — |
| 2025-09-17 | Kulkarni Samarth | Gift | 6.0K | — |
| 2025-08-18 | Kulkarni Samarth | Sell | 13K | $58.15 |
| 2025-08-16 | Kulkarni Samarth | Option exercise | 25K | — |
| 2025-08-06 | Treco Douglas A | Buy | 20K | $57.03 |
| 2025-07-16 | George Simeon | Buy | 22K | $52.03 |
| 2025-07-16 | George Simeon | Buy | 6.5K | $52.03 |
| 2025-07-16 | George Simeon | Buy | 961K | $52.03 |
| 2025-05-29 | Patel Naimish | Sell | 3.9K | $35.94 |
| 2025-05-28 | Patel Naimish | Option exercise | 10K | — |
| 2025-04-03 | Patel Naimish | Buy | 1.5K | $32.96 |
| 2025-03-21 | KASINGER JAMES R. | Sell | 3.2K | $41.23 |
| 2025-03-21 | Kulkarni Samarth | Sell | 10K | $41.23 |
| 2025-03-21 | Prasad Raju | Sell | 2.2K | $41.23 |
| 2025-03-21 | Bruno Julianne | Sell | 1.7K | $41.23 |
| 2025-03-20 | Kulkarni Samarth | Option exercise | 20K | — |
| 2025-03-20 | Bruno Julianne | Option exercise | 3.8K | — |
| 2025-03-20 | Prasad Raju | Option exercise | 6.2K | — |
| 2025-03-20 | KASINGER JAMES R. | Option exercise | 6.2K | — |
| 2025-03-17 | Prasad Raju | Sell | 3.8K | $41.80 |
| 2025-03-14 | Prasad Raju | Option exercise | 10K | — |
| 2025-03-12 | Bruno Julianne | Sell | 190 | $43.32 |
| 2025-03-12 | Kulkarni Samarth | Sell | 4.5K | $43.32 |
| 2025-03-12 | KASINGER JAMES R. | Sell | 1.1K | $43.32 |
| 2025-03-11 | KASINGER JAMES R. | Sell | 2.9K | $42.42 |
| 2025-03-11 | Kulkarni Samarth | Sell | 10.0K | $42.42 |
| 2025-03-11 | Kulkarni Samarth | Option exercise | 9.0K | — |
| 2025-03-11 | KASINGER JAMES R. | Option exercise | 2.2K | — |
| 2025-03-11 | Bruno Julianne | Sell | 1.2K | $42.42 |
| 2025-03-11 | Bruno Julianne | Option exercise | 435 | — |
| 2025-03-10 | Bruno Julianne | Option exercise | 2.4K | — |
| 2025-03-10 | KASINGER JAMES R. | Option exercise | 5.5K | — |
| 2025-03-10 | Kulkarni Samarth | Option exercise | 19K | — |
| 2025-02-26 | Greene John | Buy | 7.0K | $44.85 |
| 2025-02-19 | Kulkarni Samarth | Sell | 18K | $55.20 |
| 2025-02-19 | Bruno Julianne | Sell | 333 | $52.80 |
| 2025-02-19 | Kulkarni Samarth | Sell | 6.9K | $52.80 |
| 2025-02-19 | KASINGER JAMES R. | Sell | 1.9K | $52.80 |
| 2025-02-18 | Kulkarni Samarth | Sell | 12K | $55.05 |
| 2025-02-18 | Bruno Julianne | Option exercise | 650 | — |
| 2025-02-18 | KASINGER JAMES R. | Sell | 9.6K | $53.85 |
| 2025-02-18 | KASINGER JAMES R. | Option exercise | 3.8K | — |
| 2025-02-18 | Kulkarni Samarth | Option exercise | 13K | — |
| 2025-02-16 | KASINGER JAMES R. | Option exercise | 20K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06208878 ↗ | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies Hematologic Malignancy, Solid Malignancy | — | Enrolling By Invitation | 2038-08-01 |
| NCT07549698 ↗ | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | PHASE1/PHASE2 | Recruiting | 2033-12-01 |
| NCT05643742 ↗ | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies B-cell Lymphoma, Non-Hodgkin Lymphoma | PHASE1/PHASE2 | Recruiting | 2030-01-01 |
| NCT07491172 ↗ | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias Cardiovascular, Metabolic Disease | PHASE1 | Recruiting | 2027-06-01 |
| NCT05795595 ↗ | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors Clear Cell Renal Cell Carcinoma, Cervical Carcinoma | PHASE1/PHASE2 | Completed | 2025-09-18 |
| NCT05565248 ↗ | An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D Diabetes Mellitus, Diabetes Mellitus, Type 1 | PHASE1 | Terminated | 2025-08-08 |
| NCT04438083 ↗ | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) Renal Cell Carcinoma | PHASE1 | Terminated | 2024-10-08 |
| NCT04035434 ↗ | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) B-cell Malignancy, Non-Hodgkin Lymphoma | PHASE1/PHASE2 | Terminated | 2024-10-04 |
| NCT04502446 ↗ | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) T Cell Lymphoma | PHASE1 | Terminated | 2024-08-30 |
| NCT04244656 ↗ | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma Multiple Myeloma | PHASE1 | Terminated | 2024-01-04 |
| NCT05210530 ↗ | An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D Diabetes Mellitus, Diabetes Mellitus, Type 1 | PHASE1 | Completed | 2023-01-19 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-04 | Exec/director change5.03Shareholder voteExhibits | filing ↗ |
| 2026-05-04 | ResultsExhibits | filing ↗ |
| 2026-03-16 | Material agreementDebt obligation3.02Exhibits | filing ↗ |
| 2026-03-11 | OtherExhibits | filing ↗ |
| 2026-02-12 | ResultsExhibits | filing ↗ |
| 2026-01-12 | Other | filing ↗ |
| 2025-11-10 | ResultsExhibits | filing ↗ |
| 2025-10-15 | OtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-04 | 2026-06-04 | 0001193125-26-257593 ↗ |
| 8-K | 2026-05-04 | 2026-05-04 | 0001193125-26-204147 ↗ |
| 10-Q | 2026-05-04 | 2026-03-31 | 0001193125-26-204188 ↗ |
| 8-K | 2026-03-16 | 2026-03-16 | 0001193125-26-108333 ↗ |
| 8-K | 2026-03-11 | 2026-03-10 | 0001193125-26-101073 ↗ |
| 8-K | 2026-02-12 | 2026-02-12 | 0001193125-26-048873 ↗ |
| 10-K | 2026-02-12 | 2025-12-31 | 0001193125-26-048957 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001193125-26-009880 ↗ |
| 8-K | 2025-11-10 | 2025-11-10 | 0001193125-25-273329 ↗ |
| 10-Q | 2025-11-10 | 2025-09-30 | 0001193125-25-273337 ↗ |
| 8-K | 2025-10-15 | 2025-10-15 | 0001193125-25-240282 ↗ |
| 8-K | 2025-08-04 | 2025-08-04 | 0000950170-25-102027 ↗ |